Abstract

Using valved holding chambers (VHC) during aerosol therapy has been reported to improve the inhaled dose with various aerosol devices, including vibrating mesh nebulizers. The aim of this study was to quantify the pulmonary deposition of a jet nebulizer (JN) with and without a VHC, and a mesh nebulizer (MN) with a VHC in a randomized cross-over trial with seven healthy consenting adults. Our hypothesis was that the use of a VHC would improve deposition with the JN. Diethylnitriaminopentacetic acid with technetium (DTPA-Tc99m), with the activity of 1 mC with 0.9% saline solution was nebulized. The radiolabeled aerosol was detected by 2D planar scintigraphy after administration. The pulmonary deposition was greater with a JN with a VHC (4.5%) than a JN alone (3.2%; p = 0.005. However, an MN with a VHC (30.0%) was six-fold greater than a JN or JN with a VHC (p < 0.001). The extrapulmonary deposition was higher in the JN group without a VHC than in the other two modalities (p < 0.001). Deposition in the device was greater with a JN + VHC than an MN+/VHC (p < 0.001). Lower residual drug at the end of the dose was detected with an MN than either JN configuration. The exhaled dose was greater with a JN alone than either an MN or JN with VHC (p < 0.001). In conclusion, the addition of the VHC did not substantially improve the efficiency of aerosol lung deposition over a JN alone.

Highlights

  • Valved holding chambers (VHC) have been reported to improve the inhaled dose of medical aerosols with a variety of aerosol devices, including vibrating mesh nebulizers (MN) [1–3]

  • In vivo and in vitro studies report greater aerosol delivery using vibrating mesh nebulizers when compared to jet nebulizers (JN) [4–8]

  • These advantages are related to the physical characteristics of this device, such as low residual volume, no gas flow required to generate the aerosol and minimal disruption of ventilation compared with JNs [3,8–10]

Read more

Summary

Introduction

Valved holding chambers (VHC) have been reported to improve the inhaled dose of medical aerosols with a variety of aerosol devices, including vibrating mesh nebulizers (MN) [1–3]. VHCs were designed to provide a reservoir to collect aerosol between inhalations to improve the pulmonary deposition of inhaled medications in spontaneously breathing patients. In vivo and in vitro studies report greater aerosol delivery using vibrating mesh nebulizers when compared to jet nebulizers (JN) [4–8]. These advantages are related to the physical characteristics of this device, such as low residual volume, no gas flow required to generate the aerosol and minimal disruption of ventilation compared with JNs [3,8–10]. Developed initially for use with pressurized metered-dose inhalers (pMDIs), the VHC has been well established to improve inhaled doses while reducing dependency on inhaler techniques with performance based on the VHC design [11].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call